TARGIT-IORT is used in over 250 centres in 35 countries, and included in most national and international guidelines: 

​

Click to see an interactive world map of centres where TARGIT-IORT has been offered for breast cancer 

 

During the COVID-19 pandemic, new guidelines for treatment of breast cancer and radiotherapy especially recommend using TARGIT-IORT because it would save patients the daily travel (and viral exposure) to radiotherapy departments:

​

Global radiation oncology's targeted preparedness for COVID-19  

https://www.sciencedirect.com/science/article/pii/S2405630820300227 

“where the technology is available the use of IORT may obviate the need for any further outpatient treatment and should be considered an option ..” 

 

British Association of Cancer Surgery (BASO~ACS) https://baso.org.uk/media/98159/covid_19_and_breast_cancer_march_2020.pdf

​

German University Hospitals 

https://ro-journal.biomedcentral.com/articles/10.1186/s13014-020-01527-1

​

Italian Association of Radiotherapy and Clinical Oncology

https://www.thegreenjournal.com/article/S0167-8140(20)30221-8/fulltext

​

Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic

​https://www.futuremedicine.com/doi/10.2217/fon-2020-0574

​

Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group

https://www.geriatriconcology.net/article/S1879-4068(20)30366-0/fulltext

​

The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience

https://erc.bioscientifica.com/view/journals/erc/27/9/ERC-20-0157.xml

​

China is increasing its use of TARGIT-IORT #breastcancer by equipping more centres with the TARGIT-IORT equipment 

​

 

TARGIT-IORT has been recommended in the following guidelines on breast cancer treatment:

​

NICE, the UK National Institute for Health and Care Excellence recommended TARGIT-IORT to be used in the NHS wherever the expertise and equipment is available.

​

Marmot committee on screening mammography in the UK https://www.bmj.com/content/346/bmj.f873.full 

 

German Gynaecology Oncology group (AGO) https://www.karger.com/Article/FullText/489329 

​

German S3 guidelines https://www.awmf.org/leitlinien/detail/ll/032-045OL.html

​

St Gallen International Breast Cancer Consensus https://pubmed.ncbi.nlm.nih.gov/21709140 

 

European Society of Breast Cancer Specialists EUSOMA https://pubmed.ncbi.nlm.nih.gov/22469125/  

 

European Society of Medical Oncology ESMO https://pubmed.ncbi.nlm.nih.gov/31161190/ 

 

Australian counterpart of UK NICE - the Medical Services Advisory Committee  http://www.msac.gov.au/internet/msac/publishing.nsf/Content/4FB951393326D81CCA25801000123BF0/$File/1189-FinalPSD-IORTforEarlyBreastCancer-accessible.pdf

 

American Cancer Society  https://www.cancer.org/cancer/breast-cancer/treatment/radiation-for-breast-cancer.html 10/n

 

American Society of Breast Surgeons https://www.breastsurgeons.org/docs/statements/Consensus-Statement-for-Accelerated-Partial-Breast-Irradiation.pdf 

​

Mexican guidelines for breast cancer diagnosis and treatment 

https://www.gamo-smeo.com/files/es/gamo_21_20_supl2_001-150.pdf 

 

​